Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics' TCR Bispecific Program IMA401 Pharmaceutical Investing
Komo Plant Based Foods Continues Rapid Increase of Distribution Points with 300% Growth in 2 Months Life Science Investing
Yescarta® ZUMA-12 Study Demonstrates 78% Complete Response Rate as Part of First-Line Treatment in Newly Diagnosed High-Risk Large B-Cell Lymphoma Pharmaceutical Investing
Sirona Biochem Provides Update on SGLT2 Inhibitor for Type 2 Diabetes in China Life Science Investing
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough Pharmaceutical Investing
